血清微小RNA作为胶质瘤潜在的非侵入性生物标志物
Serum microRNAs as potential noninvasive biomarkers for glioma.
作者信息
Yu Xin, Li Zheng
机构信息
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
出版信息
Tumour Biol. 2016 Feb;37(2):1407-10. doi: 10.1007/s13277-015-4515-7. Epub 2015 Dec 1.
Gliomas are derived from astroglial precursors or astrocytes, accounting for 40 % central nervous system tumors. MicroRNAs (miRNAs) are a class of endogenous, small (19- to 23-nucleotides) non-coding RNAs involved in cancer progression. Recent studies show that circulating miRNAs are associated with the clinicopathological features and prognosis of gliomas. Serum miRNAs may serve as novel biomarkers for gliomas diagnosis. This review explores the possibilities of using serum miRNAs as prognostic, diagnostic markers, and therapeutic targets in gliomas.
胶质瘤起源于星形胶质前体细胞或星形胶质细胞，占中枢神经系统肿瘤的40%。微小RNA（miRNA）是一类内源性的小（19至23个核苷酸）非编码RNA，参与癌症进展。最近的研究表明，循环miRNA与胶质瘤的临床病理特征及预后相关。血清miRNA可能作为胶质瘤诊断的新型生物标志物。本综述探讨了将血清miRNA用作胶质瘤预后、诊断标志物及治疗靶点的可能性。
Zotero 插件